About IASO

Dr. Yongke Zhang's career began at Merck Research Labs (previously known as DNAX Research Institute) in the USA, where he worked as a Scientist, primarily responsible for developing cell cycle inhibitors for malignant tumors. He subsequently joined AbbVie (previously known as PDL Biopharma Inc.) in the USA, where he was primarily responsible for developing antibody humanization technology and therapeutic antibody. Thereafter, he worked at Epitomics in the USA, focusing on the development of therapeutic rabbit monoclonal antibody pipelines. He then joined Apexigen in the USA as Director of Preclinical Development and Clinical Research, responsible for the company's R&D and the management of early-stage clinical trials. Later, he served as Chief Executive Officer of AbCyte Therapeutics in the USA, leading the development of therapeutic antibodies and CAR-T cell therapies. Most recently, he held the position of Vice President at OBiO Tech in the USA, where he was primarily responsible for business development related to overseas outsourcing of cell and gene therapy processes.

Dr.Zhang obtained his doctor's degree in Internal Medicine, Clinical Medicine, from Health Science Center of Peking University (previously known as Beijing Medical University). He further obtained his doctor's degree in Cell and Molecular Biology from the University of Tokyo in Japan.